BETRF:OTC-BetterLife Pharma Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.074

Change

0.00 (0.00)%

Market Cap

USD 0.01B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

BetterLife Pharma Inc., a biotechnology company, primarily focuses on developing compounds for the treatment of mental disorders in Canada. It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight viral infections. The company's products pipeline includes BETR-001 for the treatment of major depressive disorder, anxiety, and neuropathic pain and other neuro-psychiatric and neurological disorders; and BETR-002 to treat benzodiazepine dependency, anxiety, and neurodegenerative disorders. It is also developing MM-003, which has completed Phase II clinical trials for the treatment of COVID-19 and other respiratory viral infections; and MM-001, a topical cream that has completed Phase II clinical trials for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-07 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
UCBJY UCB SA ADR

+0.17 (+0.18%)

USD 37.20B
UCBJF UCB SA

+10.76 (+5.85%)

USD 36.42B
ARGNF argenx SE

N/A

USD 35.17B
GNMSF Genmab A/S

+2.33 (+1.03%)

USD 14.18B
WXIBF WuXi Biologics

N/A

USD 9.23B
IVBIY IVBIY

N/A

USD 8.96B
ZLDPF Zealand Pharma A/S

-6.27 (-5.00%)

USD 8.69B
WXXWY WuXi Biologics (Cayman) Inc

+0.13 (+2.95%)

USD 8.62B
SBMFF Sino Biopharmaceutical Limited

N/A

USD 8.61B
SBHMY Sino Biopharmaceutical Ltd ADR

N/A

USD 8.43B

ETFs Containing BETRF

CRAK VanEck Oil Refiners ETF 7.47 % 0.60 %

-0.10 (2.31%)

USD 0.03B
GNR SPDR® S&P Global Natural.. 2.35 % 0.40 %

+0.49 (+2.31%)

USD 3.20B
XSOE WisdomTree Emerging Marke.. 1.65 % 0.32 %

+0.58 (+2.31%)

N/A
SPEM SPDR® Portfolio Emerging.. 1.17 % 0.12 %

+0.81 (+2.31%)

USD 10.27B
AVEM Avantis® Emerging Market.. 0.76 % 0.00 %

+1.45 (+2.31%)

USD 7.01B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 54.17% 67% D+ 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 54.17% 67% D+ 80% B-
Trailing 12 Months  
Capital Gain 57.45% 69% C- 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 57.45% 69% C- 79% B-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -25.53% 20% F 9% A-
Dividend Return -25.53% 20% F 9% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 51.43% 66% D+ 50% F
Risk Adjusted Return -49.64% 25% F 14% F
Market Capitalization 0.01B 53% F 39% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.